TY2A-DR3 Antibody

What is the TL1A-DR3 pathway and what are its key components?

The TL1A-DR3 pathway consists of TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain receptor 3 (DR3). TL1A (also known as TNFSF15) is a member of the TNF superfamily, while DR3 (also referred to as TNFRSF25) belongs to the TNF receptor superfamily. This system also includes a decoy receptor called DcR3, which indicates a tightly regulated cytokine system .

The signaling through this pathway is mediated by various death domain-containing adaptor proteins that are recruited following ligand binding. DR3 is preferentially expressed in tissues enriched with lymphocytes, suggesting its role in regulating lymphocyte homeostasis. TL1A is the sole known ligand for DR3 .

What cells express DR3 and under what conditions does expression change?

DR3 is minimally expressed on resting conventional T cells but is readily inducible upon cell activation. In contrast, it is highly expressed on resting FoxP3+ regulatory T cells (Tregs) . This differential expression pattern is significant for understanding the selective effects of TL1A-DR3 targeting.

DR3 is also expressed by various cellular subsets involved in intestinal inflammation, including intestinal epithelial cells in both mice and humans . Expression patterns can change during inflammatory conditions, with upregulation observed in active inflammatory bowel disease and other inflammatory states.

How do I detect DR3 expression in experimental samples?

DR3 expression can be detected through several techniques:

• Immunofluorescence analysis: Fixed and permeabilized cells can be stained using anti-DR3/TNFRSF25 antibodies. For instance, using recombinant rabbit monoclonal antibodies against DR3/TNFRSF25 followed by fluorescently labeled secondary antibodies allows visualization of membrane localization .

• Western blotting: Using purified antibodies such as polyclonal rabbit anti-DR3 antibodies that target specific epitopes of human DR3 (e.g., amino acid range 351-417) .

• Flow cytometry: For detecting DR3 expression on specific immune cell populations, particularly to distinguish expression levels between conventional T cells and Tregs.

• ELISA: For quantitative detection of soluble DR3 in biological samples .

For optimal results, samples should be properly fixed and, if necessary, permeabilized with agents like 0.1% Triton X-100. Nuclear counterstaining with DAPI and cytoskeletal staining with phalloidin can provide context for DR3 localization .

How does TL1A-DR3 signaling differentially affect T cell subsets, and what are the implications for experimental design?

TL1A-DR3 signaling exhibits distinct effects across different T cell subsets, requiring careful consideration in experimental design:

Effects on conventional T cells: TL1A acts as a potent co-stimulator of effector T cell responses across multiple immunophenotypes. It enhances Th1, Th2, and Th17 responses depending on the cytokine milieu . For Th2 responses, TL1A is particularly important in allergic lung inflammation models, promoting IL-13 production by NKT cells. In Th9 development, adding TL1A to culture medium with TGFβ and IL-4 greatly enhances IL-9 secretion and increases inflammatory potential .

Effects on regulatory T cells: DR3 activation with agonistic antibodies (like 4C12) or with TL1A-Ig fusion proteins leads to significant expansion of Tregs in spleen, lymph nodes, and peripheral blood. This expansion peaks around days 7-8 and returns to near baseline after 2-3 weeks. Beyond numerical expansion, DR3 agonist treatments increase activation of Tregs, with upregulation of activation markers including ICOS, KLRG-1, PD-1, CD103, and the proliferation marker Ki-67 .

Experimental design implications:

• Timing of analyses is critical - peak Treg expansion occurs around 7-8 days post-treatment

• Inclusion of multiple activation markers beyond FoxP3 is necessary to fully characterize Treg responses

• Consideration of tissue distribution patterns (blood vs. lymphoid organs) is important

• RNA-sequencing analysis reveals subtly different patterns of Treg activation by different DR3 agonists

When studying conventional T cells, researchers should account for the co-stimulatory environment, as TL1A effects are context-dependent and vary based on concurrent cytokine signaling.

What are the methodological challenges in studying the homeostatic versus inflammatory roles of TL1A-DR3?

The TL1A-DR3 axis presents intriguing paradoxes in its biological functions, as it appears to play both pro-inflammatory and homeostatic roles depending on context. This duality creates several methodological challenges:

Conflicting observations in different model systems: In DSS-induced colitis models, DR3-deficient mice develop more severe inflammation compared to wild-type mice, suggesting a homeostatic role. Conversely, in other inflammatory models, TL1A-DR3 signaling promotes inflammation . When designing experiments, researchers must carefully select models that align with their specific research questions and interpret results within the appropriate context.

Cell type-specific functions: TL1A-DR3 signaling affects various cell populations differently. For example:

• Promotes effector functions in conventional T cells

• Expands regulatory T cells under certain conditions

• Influences innate lymphoid cells (particularly Group 3 ILCs)

• Affects intestinal epithelial cells and macrophage functions

To address this complexity, experiments should include:

• Cell-specific conditional knockout models rather than global knockouts

• Comprehensive analysis of multiple immune populations simultaneously

• Time-course experiments to capture dynamic changes in signaling effects

• Combined in vitro and in vivo approaches to validate observations

Genetic variation effects: Discovery of genetic polymorphisms with functional consequences in the TL1A (TNFSF15) gene adds another layer of complexity. These variations may allow for patient stratification and predict differential responses to TL1A-targeted therapeutics . Researchers should consider genetic background effects when using animal models and potentially incorporate genotyping in human studies.

What are the optimal parameters for using DR3 agonists to expand regulatory T cells in experimental settings?

Based on the research data, optimal parameters for using DR3 agonists to expand regulatory T cells include:

Agonist selection: Both agonistic antibodies (such as 4C12) and fusion proteins incorporating the natural DR3 ligand (TL1A-Ig) effectively expand Tregs. The choice depends on experimental goals:

• Agonistic antibodies have longer half-lives but may raise safety concerns

• TL1A-Ig fusion proteins offer a more physiological approach

Dosing and timing:

• Peak Treg expansion occurs around days 7-8 post-treatment

• Return to near baseline happens after 2-3 weeks

• This temporal pattern should guide experimental timelines

Combination with other agents: Adding low-dose IL-2 to DR3 agonist treatment regimens can enhance Treg expansion effects. This combination approach may be particularly useful for more robust experimental outcomes .

Assessment markers: Beyond quantitative expansion, researchers should evaluate qualitative changes including:

• Activation markers: ICOS, KLRG-1, PD-1, and CD103

• Proliferation markers: Ki-67

• Functional capacity using suppression assays

• Transcriptional profiling via RNA-sequencing to detect changes in genes related to proliferation, trafficking, activation, and effector function

Functional validation: In models like MHC-mismatched hematopoietic cell transplantation, confirming that expanded Tregs maintain suppressive function is essential. DR3 agonist-mediated expansion and activation of Tregs in donor mice significantly improved graft-versus-host disease outcomes in recipient mice, confirming functional relevance .

How can TL1A-DR3 targeting be applied in inflammatory bowel disease (IBD) research models?

The TL1A-DR3 pathway offers significant research opportunities in IBD models due to its multifaceted roles in intestinal inflammation:

Genetic correlation studies: Polymorphisms in TNFSF15 (encoding TL1A) have functional consequences that may allow for patient stratification in IBD. Research designs should incorporate genetic analysis to correlate TNFSF15 variants with disease phenotypes and response to therapies .

Dual approach rationale: Experimental designs should account for the dual nature of TL1A-DR3 signaling in IBD pathogenesis:

• Pro-inflammatory pathways: TL1A-DR3 signaling potently co-stimulates effector immune responses that contribute to intestinal inflammation. Blockade approaches using:

  • Anti-TL1A antibodies

  • Anti-DR3 antibodies

  • Decoy receptors mimicking DcR3

  These can be evaluated in models such as SAMP mice (which develop CD-like ileitis) or DSS-induced colitis .

• Homeostatic mechanisms: TL1A-DR3 also participates in innate immune pathways mediating post-injury repair, epithelial barrier integrity, and host defense against pathogens. This suggests caution in complete pathway blockade and opportunities for targeted enhancement of these protective functions .

Methodological considerations:

• Timing of intervention is critical (preventive vs. therapeutic)

• Cell-type specific targeting (using conditional knockout or cell-specific delivery systems)

• Combined endpoints measuring both inflammation and tissue remodeling/fibrosis

• Inclusion of microbiome analysis, as TL1A-DR3 affects interactions with intestinal bacteria

For fibrosis studies specifically, TL1A-DR3 signaling in stromal cells may contribute to intestinal fibrogenesis, making this pathway relevant for studying fibrostenotic complications of IBD .

What are the technical considerations for investigating TL1A-DR3 in transplantation immunology?

Investigating the TL1A-DR3 pathway in transplantation models requires specific technical considerations:

Timing of DR3 agonist administration:

• Pre-treatment of donor mice with DR3 agonists (antibodies or TL1A-Ig) leads to significant expansion and activation of Tregs

• Peak expansion occurs around days 7-8, suggesting optimal timing for cell harvest or transplantation procedures

• The expanded Treg population maintains significant presence for 2-3 weeks before returning to baseline

Tracking expanded Tregs: Bioluminescent imaging offers a non-invasive approach to monitor Treg expansion dynamics in vivo. This technique can be particularly valuable for validating treatment effects before proceeding with transplantation experiments .

Phenotypic characterization:

• Flow cytometry with tSNE analysis can reveal activated Treg populations that are nearly absent in control-treated specimens

• Key markers to assess include ICOS, KLRG-1, PD-1, CD103, and Ki-67

• RNA-sequencing provides deeper insights into transcriptional changes affecting cell proliferation, trafficking, activation, and effector function

Transplantation model selection:

• The major MHC-mismatch model of hematopoietic cell transplantation has been validated for studying DR3 agonist effects

• Experimental designs should include appropriate control groups to distinguish effects of DR3-expanded Tregs from other variables

Evaluation of GVHD outcomes:

• Clinical scoring systems

• Histopathological analysis of target organs

• Survival analysis

• Immune reconstitution parameters

This approach has demonstrated that DR3 agonist-mediated expansion and activation of Tregs in donor mice leads to significant improvement in GVHD outcomes in recipient mice, providing a promising research direction for transplantation immunology .

How should researchers interpret conflicting data on TL1A-DR3 pathway in different disease models?

Interpreting conflicting data on the TL1A-DR3 pathway across different disease models requires systematic analysis:

Context-dependent signaling effects: TL1A-DR3 signaling outcomes are highly dependent on:

• Disease context: The pathway shows different effects in allergic inflammation versus intestinal inflammation versus transplantation settings

• Cell types involved: Effects on conventional T cells differ dramatically from effects on Tregs

• Genetic background: Both in mouse strains and human polymorphisms

Methodological factors to consider:

• Timing of intervention relative to disease onset

• Route of administration for targeting agents

• Dosage effects (partial versus complete inhibition)

• Development of compensatory mechanisms in genetic knockout models

Analytical framework for resolving conflicts:

• Temporal dynamics analysis: Short-term versus long-term effects may differ substantially

• Dose-response relationships: Threshold effects may explain seemingly contradictory results

• Comprehensive immune profiling: Beyond target validation, examine how pathway modulation affects the broader immune landscape

• Multi-omics integration: Combine transcriptomics, proteomics, and functional analyses to obtain a systems-level view

When data conflicts appear, researchers should consider that TL1A-DR3 has been demonstrated to play "a central and multifaceted role in the immunological pathways that underlie intestinal inflammation" . This multifaceted nature means that seemingly contradictory results may actually reveal different aspects of a complex signaling system with context-dependent functions.

What are the optimal antibody selection criteria for different TL1A-DR3 pathway research applications?

Selecting the appropriate antibodies for TL1A-DR3 research requires matching reagent properties to specific applications:

For DR3 detection and localization studies:

• Immunohistochemistry/Immunofluorescence: Choose antibodies validated for fixed tissues or cells, such as polyclonal rabbit anti-DR3 antibodies targeting specific epitopes (e.g., amino acid range 351-417 of human DR3) . For optimal results:

  • Use appropriate fixation protocols (e.g., formalin fixation)

  • Include permeabilization steps (0.1% Triton X-100) for intracellular epitopes

  • Validate with positive and negative controls

• Flow cytometry: Select antibodies that recognize native protein conformations in non-fixed cells. Considerations include:

  • Fluorophore brightness matched to expression level

  • Clone validation for specific cell types

  • Titration to determine optimal concentration

For functional modulation studies:

• Agonistic applications: For Treg expansion, both agonistic antibodies (like 4C12) and fusion proteins (TL1A-Ig) are effective. Consider:

  • Antibody half-life (longer for potential therapeutic applications)

  • Fc-mediated effects (relevant for in vivo applications)

  • Potential for combination with low-dose IL-2

• Antagonistic applications: For blocking TL1A-DR3 signaling in inflammatory models:

  • Epitope targeting (functional blocking requires binding to interaction interfaces)

  • Isotype controls matched to blocking antibodies

  • Validation of functional blockade through downstream signaling assays

Source considerations:

• Monoclonal antibodies provide consistent lot-to-lot reproducibility

• Recombinant rabbit monoclonal antibodies offer advantages in specificity

• Polyclonal antibodies may provide broader epitope recognition

How can researchers effectively monitor TL1A-DR3 signaling activation in experimental systems?

Monitoring TL1A-DR3 signaling activation requires multi-dimensional approaches targeting different aspects of the signaling cascade:

Proximal signaling events:

• Receptor clustering and internalization: Monitor DR3 surface expression changes following ligand binding using flow cytometry or immunofluorescence microscopy

• Adaptor protein recruitment: Immunoprecipitation of DR3 followed by western blotting for death domain-containing adaptor proteins

• Post-translational modifications: Phospho-specific antibodies to detect activation of downstream kinases in the signaling pathway

Transcriptional responses:

• RNA-sequencing: Provides comprehensive view of transcriptional changes following DR3 activation, revealing gene transcripts involved in cell proliferation, trafficking, activation, and effector function

• qRT-PCR: For targeted analysis of key pathway-responsive genes

• Transcription factor activation: Nuclear translocation of NF-κB can be monitored by immunofluorescence or nuclear/cytoplasmic fractionation followed by western blotting

Functional readouts:

• Cell proliferation: Ki-67 staining by flow cytometry or immunohistochemistry to quantify proliferative responses

• Activation marker upregulation: Monitor expression of ICOS, KLRG-1, PD-1, and CD103 on T cells as indicators of DR3-mediated activation

• Cytokine production: Measure TL1A-enhanced cytokine secretion (e.g., IL-9, IL-13) by ELISA or intracellular cytokine staining

• Functional assays: For Tregs, suppression assays measuring inhibition of responder T cell proliferation

In vivo monitoring techniques:

• Bioluminescent imaging: Allows longitudinal tracking of Treg expansion in vivo after DR3 agonist treatment

• Multi-parameter flow cytometry: tSNE analysis can reveal distinct activation patterns between treatment groups

• Tissue-specific responses: Comparing effects across spleen, lymph nodes, and peripheral blood provides insights into tissue-specific signaling outcomes

When designing monitoring protocols, researchers should account for the temporal dynamics of TL1A-DR3 signaling, with peak effects on Treg expansion occurring around days 7-8 and returning to near baseline after 2-3 weeks .

What are the critical quality control parameters for antibodies targeting the TL1A-DR3 pathway?

Ensuring antibody quality is essential for generating reliable and reproducible research on the TL1A-DR3 pathway. Critical quality control parameters include:

Specificity validation:

• Western blot analysis: Confirm single band of expected molecular weight (DR3: ~47 kDa)

• Knockout/knockdown controls: Test antibodies on DR3-deficient samples to confirm specificity

• Peptide competition: Pre-incubation with immunizing peptide should abolish specific staining

• Cross-reactivity testing: Validate antibody performance across species (human, mouse, rat) if cross-reactivity is claimed

Functional validation for modulatory antibodies:

• Dose-response relationships: Establish quantitative measures of agonism/antagonism

• Downstream signaling effects: Confirm expected molecular consequences of receptor engagement

• Comparison with recombinant ligand: Benchmark antibody effects against natural ligand (TL1A)

• In vivo validation: Confirm that in vitro effects translate to expected in vivo outcomes (e.g., Treg expansion)

Application-specific performance metrics:

• Immunohistochemistry/Immunofluorescence:

  • Signal-to-noise ratio

  • Consistent staining pattern (e.g., membrane localization for DR3)

  • Reproducibility across different sample preparations

• Flow cytometry:

  • Staining index compared to isotype controls

  • Consistency of median fluorescence intensity

  • Performance in different buffer conditions

• Western blotting:

  • Limit of detection

  • Linear dynamic range

  • Lot-to-lot consistency

Storage and handling validation:

• Stability testing: Confirm activity after storage at recommended conditions (-20°C with glycerol)

• Freeze-thaw stability: Determine maximum number of freeze-thaw cycles

• Working dilution optimization: Establish optimal concentration for each application (e.g., 1 μg/μl for certain applications)

Researchers should maintain detailed records of antibody performance across experiments and consider establishing reference standards within their laboratory to ensure consistent interpretation of results when studying the TL1A-DR3 pathway.

How might TL1A-DR3 targeting be integrated with other immune checkpoint approaches?

The integration of TL1A-DR3 targeting with other immune checkpoint approaches represents an exciting frontier with several strategic considerations:

Complementary biological mechanisms:

• Combination with PD-1/PD-L1 targeting: While PD-1 pathways primarily inhibit effector T cell functions, TL1A-DR3 can both enhance effector responses and expand regulatory T cells. This dual effect could be leveraged to create more nuanced immunomodulation depending on the disease context .

• Integration with IL-2 pathway modulation: Low-dose IL-2 has been shown to enhance DR3 agonist-mediated Treg expansion. This combinatorial approach could be further refined by using IL-2 complexes or engineered IL-2 variants with selective binding properties .

• Combination with TNF superfamily modulators: Since DR3 belongs to the TNF receptor superfamily, there may be synergistic or antagonistic effects when combining with other TNFR-targeted therapies that should be systematically evaluated.

Experimental design considerations:

• Sequential versus simultaneous targeting: Timing of interventions may significantly impact outcomes (e.g., priming with DR3 agonist before checkpoint blockade)

• Dose optimization: Finding the optimal balance between pathways to avoid toxicity while maintaining efficacy

• Cell type-specific effects: Monitoring changes across multiple immune populations simultaneously

• Biomarker development: Identifying predictive markers of response to combination approaches

Disease-specific strategies:

• Inflammatory bowel disease: Combining TL1A blockade with other gut-specific immune modulators might enhance efficacy while limiting systemic effects .

• Transplantation: DR3 agonism for Treg expansion could be combined with targeted conventional T cell suppression for more complete prevention of graft rejection or GVHD .

• Autoimmune conditions: Balancing regulatory and effector targeting based on disease immunophenotype.

Translational pathway considerations:
As these combination approaches move closer to clinical application, researchers should establish robust preclinical models that accurately predict human responses, develop companion diagnostics to identify suitable patients, and carefully monitor for unexpected immune-related adverse events that might arise from pathway interactions.

What are the implications of genetic polymorphisms in the TL1A-DR3 pathway for experimental design and data interpretation?

Genetic polymorphisms in the TL1A-DR3 pathway have significant implications for both experimental design and interpretation of research findings:

Impact on experimental design:

• Model selection considerations:

  • Different mouse strains may harbor genetic variants affecting TL1A-DR3 signaling

  • Humanized mouse models may be necessary to study human-specific polymorphisms

  • CRISPR-engineered models introducing specific polymorphisms can isolate their effects

• Study design elements:

  • Genetic screening/genotyping should be incorporated into experimental workflows

  • Stratification of experimental subjects based on genotype

  • Power calculations should account for genetic heterogeneity

• In vitro systems:

  • Primary cells from genotyped donors versus cell lines

  • Isogenic cell lines with engineered polymorphisms to control for genetic background

Data interpretation frameworks:

• Functional consequences of polymorphisms:

  • TNFSF15 (TL1A) polymorphisms have demonstrated functional effects and may predict differential responses to TL1A-targeted therapeutics

  • Polymorphisms may affect ligand-receptor binding affinity, signaling strength, or pathway regulation

• Context-dependent effects:

  • Environmental triggers may be required to reveal phenotypes associated with certain variants

  • Cell type-specific consequences of the same genetic variant

• Population differences:

  • Frequency and impact of polymorphisms may vary across ethnic groups

  • Consideration of evolutionary selection pressures on these variants

Methodological considerations for polymorphism studies:

• Functional validation approaches:

  • Reporter assays measuring pathway activation

  • Binding affinity measurements

  • Cell-based functional assays comparing variant effects

• Analytical approaches:

  • Multivariable analyses accounting for genetic and environmental factors

  • Machine learning methods to identify complex genotype-phenotype relationships

  • Systems biology approaches integrating genetic variation with pathway modeling

• Reproducibility considerations:

  • Validation across multiple cohorts

  • Meta-analyses of polymorphism effects

  • Careful documentation of genetic background in model systems

Understanding these polymorphisms may ultimately enable patient stratification for personalized therapeutic approaches targeting the TL1A-DR3 pathway, particularly in conditions like inflammatory bowel disease where genetic associations have been established .

How can researchers effectively apply TL1A-DR3 pathway knowledge in developing new therapeutic approaches?

Translating TL1A-DR3 pathway knowledge into therapeutic development requires strategic approaches bridging basic research and therapeutic applications:

Target selection strategies:

• Pathway component targeting:

  • TL1A neutralization: Antibodies binding the ligand to prevent receptor interaction

  • DR3 blockade: Antibodies preventing ligand binding to the receptor

  • DR3 agonism: For therapeutic Treg expansion in transplantation or autoimmunity

  • Decoy receptor mimics: Engineered versions of DcR3 to scavenge TL1A

• Context-specific targeting:

  • Cell type-selective delivery systems

  • Tissue-targeted approaches for localized effects

  • Temporal control of pathway modulation

Preclinical development considerations:

• Model selection:

  • Models should recapitulate the specific aspect of TL1A-DR3 biology being targeted

  • For IBD applications, models capturing both inflammation and fibrosis are important

  • For transplantation applications, major MHC-mismatch models have demonstrated utility

• Pharmacodynamic biomarkers:

  • For agonistic approaches: Treg expansion and activation markers (ICOS, KLRG-1, PD-1, CD103)

  • For antagonistic approaches: Reduction in TL1A-induced cytokine production

  • Tissue-specific pathway activity indicators

• Pharmacokinetic considerations:

  • Antibody half-life optimization (shorter for agonists to minimize toxicity risks)

  • Tissue distribution profiles

  • Route of administration effects

Safety and efficacy prediction:

• Therapeutic window considerations:

  • Given the dual role of TL1A-DR3 in both inflammation and homeostasis, complete inhibition may disrupt beneficial functions

  • Dose-finding studies are critical to establish optimal biological effect

• Predictive biomarkers:

  • Genetic polymorphisms in TNFSF15 may predict response to TL1A-targeted therapeutics

  • Baseline immune phenotyping to identify likely responders

• Monitoring for off-target effects:

  • Effects on host defense against infections, particularly intracellular bacteria

  • Impacts on barrier function in mucosal tissues

  • Unexpected effects on other TNF family signaling pathways

Translational research approaches:

• Human sample validation:

  • Ex vivo testing in patient-derived samples

  • Humanized mouse models

  • Target expression confirmation in relevant disease tissues

• Combination strategies:

  • With low-dose IL-2 for enhanced Treg expansion

  • With standard-of-care therapies for specific indications

  • Sequential treatment protocols based on disease stage

This systematic approach to therapeutic development builds on the foundational understanding that "TL1A:DR3 signaling plays a central and multifaceted role in the immunological pathways that underlie intestinal inflammation," providing "the foundation for developing pharmaceutical approaches targeting this ligand-receptor pair" .